Dhampur Bio

Why is Dhampur Bio Organics Ltd falling/rising?

As of 13-Jul, Dhampur Bio Organics Ltd's stock price has risen to Rs 117.35, up 4.78%, driven by strong recent performance and positive sector trends, despite a decline in investor participation. The stock is trading above its moving averages, indicating bullish momentum.

As of 13-Jul, Dhampur Bio Organics Ltd is experiencing a rise in its stock price, currently at Rs 117.35, reflecting an increase of Rs 5.35 or 4.78%. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 4.73% while the Sensex has declined by 0.85%. Additionally, the stock has shown a strong performance over the last two days, with a total increase of 6.2% during this period.<BR><BR>The stock also reached an intraday high of Rs 117.55, indicating positive trading momentum. Furthermore, Dhampur Bio is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a bullish signal for investors. The sugar sector, in which the company operates, has also seen a gain of 2.85%, contributing to the positive sentiment around the stock.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 47.21% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, which may help sustain its current price level. Overall, the combination of strong recent performance, positive sector trends, and favorable moving averages supports the rise in Dhampur Bio Organics Ltd's stock price.

Which are the latest news on Dhampur Bio?

When is the next results date for Dhampur Bio Organics Ltd?

The next results date for Dhampur Bio Organics Ltd is 14 July 2026.

The next results date for Dhampur Bio Organics Ltd is scheduled for 14 July 2026.

What does Dhampur Bio do?

Dhampur Bio Organics Ltd, a micro-cap company in the sugar industry, was incorporated in 2020 and reported net sales of 540 Cr and a net profit of 46 Cr for March 2026. Key metrics include a P/E of 29.00 and a market cap of INR 737 Cr.

Overview: <BR>Dhampur Bio Organics Ltd operates in the sugar industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 2020 under the name "RMSD Enterprises Private Limited" and later converted to a public limited company named "Dhampur Bio Organics Limited" in 2021. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 540 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 46 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 737 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 19 <BR>Dividend Yield: 1.08% <BR>Debt Equity: 1.00 <BR>Return on Equity: 2.45% <BR>Price to Book: 0.72 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Dhampur Bio?

As of 10th June, Dhampur Bio Organics Ltd has a market capitalization of 737.00 Cr and reported net sales of 2109.25 Cr and a net profit of 25.18 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Dhampur Bio Organics Ltd has a market capitalization of 737.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2109.25 Cr, while the sum of Net Profit for the same period is 25.18 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,011.74 Cr, and Total Assets amount to 2,397.53 Cr.

Who are in the management team of Dhampur Bio?

The management team of Dhampur Bio includes V K Goel (Executive Chairman), A K Gupta (Vice Chairman), Gautam Goel (Managing Director), and several independent directors, along with Ashu Rawat as Company Secretary. They are responsible for the company's strategic direction and operations.

The management team of Dhampur Bio includes the following key individuals:<BR><BR>1. **V K Goel** - Executive Chairman<BR>2. **A K Gupta** - Vice Chairman<BR>3. **Gautam Goel** - Managing Director<BR>4. **Sandeep Kumar Sharma** - Whole-time Director<BR>5. **Bindu Vashist Goel** - Director<BR>6. **Ruchika Mehra Kothari** - Independent Director<BR>7. **Vishal Saluja** - Independent Director<BR>8. **Samir Thukral** - Independent Director<BR>9. **Kishor Shah** - Independent Director<BR>10. **Ashu Rawat** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Dhampur Bio?

Dhampur Bio's peers include Avadh Sugar, Dhampur Sugar, Uttam Sug.Mills, Dwarikesh Sugar, Zuari Industries, Magadh Sugar, Davangere Sugar, DCM Shriram Inds, Ugar Sugar Works, and Mawana Sugars. Dhampur Bio has the highest 1-year return at 37.10% among its peers, while most exhibit below-average growth and capital structure ratings.

Peers: The peers of Dhampur Bio are Avadh Sugar, Dhampur Sugar, Uttam Sug.Mills, Dwarikesh Sugar, Zuari Industries, Magadh Sugar, Davangere Sugar, DCM Shriram Inds, Ugar Sugar Works, and Mawana Sugars.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dwarikesh Sugar, while Average management risk is found at Avadh Sugar, Dhampur Sugar, Uttam Sug.Mills, Dhampur Bio, Magadh Sugar, DCM Shriram Inds, Ugar Sugar Works, and Mawana Sugars. Below Average management risk is noted at Zuari Industries and Davangere Sugar. All peers exhibit Below Average growth, except for Dwarikesh Sugar, which has Average growth. Capital Structure ratings are Below Average for Avadh Sugar, Dhampur Sugar, Uttam Sug.Mills, Dhampur Bio, Zuari Industries, Magadh Sugar, and Davangere Sugar, while Dwarikesh Sugar and DCM Shriram Inds have Average capital structure.<BR><BR>Return Snapshot: Dhampur Bio has a 1-year return of 37.10%, which is the highest among its peers, while Magadh Sugar has the lowest at -38.66%. Dhampur Bio's return significantly outperforms all its peers. Additionally, peers such as Zuari Industries, Magadh Sugar, DCM Shriram Inds, and Ugar Sugar Works have negative six-month returns.

Should I buy, sell or hold Dhampur Bio Organics Ltd?

Are Dhampur Bio Organics Ltd latest results good or bad?

Dhampur Bio Organics Ltd's latest results show a significant quarterly profit increase of 205.69%, but a concerning year-over-year decline of 346.36%. While there are signs of recovery, ongoing challenges in profitability and below-average returns suggest caution for investors.

Dhampur Bio Organics Ltd's latest results present a mixed picture. In Q3 FY26, the company reported a net profit of ₹16.90 crores, which is a significant improvement of 205.69% compared to the previous quarter. This indicates a positive turnaround in profitability after experiencing losses in earlier quarters. However, on a year-over-year basis, the net profit reflects a concerning decline of 346.36%.<BR><BR>Revenue for the same quarter was ₹486.34 crores, which shows a decline of 12.79% from the previous quarter but an increase of 4.74% compared to the same quarter last year. This revenue drop is typical for the sugar industry due to seasonal fluctuations.<BR><BR>While the operating margin improved to 8.77% from a negative figure in the previous quarter, the overall financial health of the company raises some concerns. The cumulative net loss for the nine months ending December 2025 was ₹21.09 crores, indicating ongoing challenges in maintaining consistent profitability.<BR><BR>Furthermore, the company's return on equity (ROE) and return on capital employed (ROCE) are significantly below industry standards, suggesting inefficiencies in capital utilization. The high reliance on non-operating income to achieve profit also casts doubt on the sustainability of these results.<BR><BR>In summary, while there are signs of recovery in the latest quarter, the overall financial performance remains under pressure, and the company faces significant challenges in the competitive sugar sector. Investors should weigh these factors carefully when assessing the company's outlook.

Is Dhampur Bio technically bullish or bearish?

As of December 2, 2025, Dhampur Bio's technical trend is neutral with mixed indicators, showing a mildly bearish weekly and monthly MACD, mildly bullish daily moving averages, and a lack of strong momentum overall.

As of 2 December 2025, the technical trend for Dhampur Bio has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The Bollinger Bands also reflect a mildly bearish sentiment on both weekly and monthly time frames. However, the daily moving averages show a mildly bullish signal, suggesting some short-term strength. The Dow Theory indicates a mildly bullish stance on the weekly chart, but no trend is present on the monthly chart. Overall, the technical indicators present a conflicting picture, leading to a neutral stance with no strong bullish or bearish momentum.

How has been the historical performance of Dhampur Bio?

Dhampur Bio's historical performance shows a decline in net sales, operating profit, and profit after tax over the past four years, with significant drops from March 2023 to March 2025, despite an increase in total assets and liabilities. Cash flow from operating activities turned negative in March 2024, indicating a downward trend in profitability.

Answer:<BR>The historical performance of Dhampur Bio shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Dhampur Bio's net sales for the year ending March 2025 were reported at 1,861.54 crore, slightly down from 1,864.44 crore in March 2024 and significantly lower than 2,407.53 crore in March 2023. The total operating income mirrored this trend, remaining almost flat from the previous year but showing a decline from the prior two years. The total expenditure, excluding depreciation, was 1,726.74 crore in March 2025, a minor decrease from 1,728.01 crore in March 2024, yet lower than 2,202.81 crore in March 2023. Operating profit (PBDIT) for March 2025 was 138.46 crore, down from 160.30 crore in March 2024 and 216.14 crore in March 2023. Profit before tax also saw a decline to 15.71 crore in March 2025 from 65.49 crore in March 2024 and 134.77 crore in March 2023. Consequently, profit after tax dropped to 14.69 crore in March 2025 from 46.49 crore in March 2024 and 111.10 crore in March 2023. The company's total assets increased to 2,397.53 crore in March 2025 from 2,312.81 crore in March 2024, while total liabilities also rose to 2,397.53 crore from 2,312.81 crore in the same period. Cash flow from operating activities turned negative at -101 crore in March 2024, contrasting with a positive cash flow of 368 crore in March 2023. Overall, the financial performance of Dhampur Bio indicates a downward trend in profitability and sales over the last few years, despite an increase in total assets and liabilities.

Is Dhampur Bio overvalued or undervalued?

As of October 10, 2025, Dhampur Bio is considered very attractive and undervalued, with a PE ratio of -95.86, a low price-to-book value of 0.54, and an EV to EBITDA ratio of 16.15, especially when compared to peers like EID Parry and Balrampur Chini, despite its year-to-date stock performance lagging at -28.53% against the Sensex's 5.58%.

As of 10 October 2025, the valuation grade for Dhampur Bio has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, particularly when analyzing its key ratios. The PE ratio stands at -95.86, while the price-to-book value is a low 0.54, suggesting that the stock is trading well below its book value. Additionally, the EV to EBITDA ratio is 16.15, which, while higher than some peers, still reflects a favorable valuation in the context of the overall market.<BR><BR>In comparison to its peers, Dhampur Bio's valuation metrics stand out. EID Parry, categorized as very expensive, has a PE ratio of 23.46, while Balrampur Chini, rated fair, shows a PE of 23.07. This stark contrast highlights Dhampur Bio's undervaluation relative to its competitors. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -28.53% compared to the Sensex's 5.58%. This underperformance reinforces the notion that the stock may be undervalued, presenting a potential opportunity for investors.

Who are the top shareholders of the Dhampur Bio?

The top shareholders of Dhampur Bio include Sonitron Limited with 17.28%, individual investor Anil Kumar Goel at 9.04%, and individual investors collectively holding 40.43%. Additionally, 12 foreign institutional investors hold 0.54%, while mutual funds have no significant holdings.

The top shareholders of Dhampur Bio include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sonitron Limited, which owns 17.28% of the company. In terms of public shareholders, Anil Kumar Goel is the largest individual investor, holding 9.04%. Additionally, individual investors collectively hold 40.43% of the shares. There are also 12 foreign institutional investors (FIIs) with a combined holding of 0.54%, and three mutual fund schemes that hold 0.0%.

Has Dhampur Bio declared dividend?

Yes, Dhampur Bio Organics Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of June 28, 2024. However, the company has experienced significant price declines, resulting in total returns of -38.81% over the last 6 months and -34.19% over the past year.

Dhampur Bio Organics Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 3.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -38.81%, the dividend return was 0%, resulting in a total return of -38.81%.<BR><BR>Over the past year, the price return was -36.03%, with a dividend return of 1.84%, leading to a total return of -34.19%.<BR><BR>For the 2-year period, the price return was -50.95%, the dividend return was 3.35%, culminating in a total return of -47.6%.<BR><BR>In the 3-year timeframe, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Dhampur Bio has declared a dividend, the total returns over various periods indicate significant declines in price, particularly over the last 6 months and 1 year, highlighting a challenging performance despite the dividend yield.